FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 06/2023”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the US-Biotech sector.
As of the tip of June 2023, we determine the next present VC traits within the US-Biotech sector:
- In 2023, total Biotech funding within the USA has reached USD 9,562m
- In comparison with June 2022 the financing quantity decreased twofold (20,106m vs. 9,562m)
- Oncology dominates as the highest indication
- Upstream Bio has the best transaction Quantity of USD 200m in June, adopted by Alkeus Prescription drugs USD 150m and Bitterroot Bio USD 145m
- ARCH Enterprise Companions (USA) is main the High 5 Buyers (by deal quantity), adopted by Alexandria Enterprise Investments (USA) and Google Ventures (USA)
- The highest 5 offers exceed USD 190m every, largest transaction amounted to USD 401m in ElevateBio
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marcel-Louis Christou.